C4 Therapeutics
CCCC
125 hedge funds and large institutions have $905M invested in C4 Therapeutics in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 23 closing their positions.
148% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $5.3M
47% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 32
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
5% more funds holding
Funds holding: 119 → 125 (+6)
2.76% more ownership
Funds ownership: 73.81% → 76.58% (+2.8%)
22% less capital invested
Capital invested by funds: $1.15B → $905M (-$249M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$49.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.5M |
| 3 |
PVI
Pura Vida Investments
New York
|
+$14.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$44.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$32.1M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$18.7M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$9.58M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$7.91M |
CCCC Hedge Fund Activity: Q1 2022 in Review
125 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2022, worth a combined $905M — down 22% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CCCC positions and 23 closed out — a net gain of 6 holders — while 47 added to existing stakes and 32 trimmed.
The largest buyer was RTW Investments, adding an estimated $49.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $44.4M sold.
- 125 institutional investors held C4 Therapeutics (CCCC) as of Q1 2022, up from 119 in Q4 2021.
- Funds reported $905M of C4 Therapeutics stock for Q1 2022, down 22% quarter-over-quarter.
- 29 funds opened new C4 Therapeutics positions in Q1 2022 and 23 closed out, a net change of +6 holders.
- The largest C4 Therapeutics buyer in Q1 2022 was RTW Investments, an estimated $49.5M added.
- The largest C4 Therapeutics seller in Q1 2022 was RA Capital Management, an estimated $44.4M sold.
Based on aggregated 13F filings for Q1 2022.